Back to all studies
TerminatedNCT05368558

Cariprazine for schizophrenia

This study was terminated in Japan and in Taiwan. It is testing cariprazine for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Cariprazine may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Cariprazine, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan and in Taiwan.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 18, 2022
Recruitment status
Terminated
Enrollment listed in the registry
34
Sponsor
AbbVie
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan, Taiwan
Age range
From 18 Years to 65 Years
Official registry ID
NCT05368558
Official title
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT05368558. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Japan · 37 sites
  • Akita University Hospital /ID# 245941
    Akita, Akita
    Site status: Not listed — confirm with the team
  • International University of Health and Welfare Narita Hospital /ID# 243870
    Narita-shi, Chiba
    Site status: Not listed — confirm with the team
  • Fukuoka University Hospital /ID# 244404
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Kuramitsu Hospital /ID# 242511
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Shiranui Hospital /ID# 243717
    Omuta-shi, Fukuoka
    Site status: Not listed — confirm with the team
  • Gifu University Hospital /ID# 246238
    Gifu, Gifu
    Site status: Not listed — confirm with the team
  • Holy Cross Hospital /ID# 242673
    Toki-shi, Gifu
    Site status: Not listed — confirm with the team
  • Hayakawa Clinic /ID# 242432
    Kure, Hiroshima
    Site status: Not listed — confirm with the team
  • National Hospital Organization Kure Medical Center /ID# 243405
    Kure-shi, Hiroshima
    Site status: Not listed — confirm with the team
  • Goryokai Hospital /ID# 242420
    Sapporo, Hokkaido
    Site status: Not listed — confirm with the team
  • Sapporo Medical University Hospital /ID# 245135
    Sapporo, Hokkaido
    Site status: Not listed — confirm with the team
  • Duplicate_Hokkaido University Hospital /ID# 243245
    Sapporo, Hokkaido
    Site status: Not listed — confirm with the team
  • Kagawa University Hospital /ID# 243772
    Kita-gun, Kagawa-ken
    Site status: Not listed — confirm with the team
  • Taniyama Hospital /ID# 242385
    Kagoshima, Kagoshima-ken
    Site status: Not listed — confirm with the team
  • Yokohama City University Hospital /ID# 244944
    Yokohama, Kanagawa
    Site status: Not listed — confirm with the team
  • Yuge Hospital /ID# 242849
    Kumamoto, Kumamoto
    Site status: Not listed — confirm with the team
  • Duplicate_University Hospital Kyoto Prefectural University of Medicine /ID# 242443
    Kyoto, Kyoto
    Site status: Not listed — confirm with the team
  • Maizuru Medical Center /ID# 243450
    Maizuru, Kyoto
    Site status: Not listed — confirm with the team
  • Mie University Hospital /ID# 244710
    Tsu, Mie-ken
    Site status: Not listed — confirm with the team
  • Mental Support Soyokaze Hospital /ID# 242512
    Ueda-shi, Nagano
    Site status: Not listed — confirm with the team
  • Nara Medical University Hospital /ID# 242561
    Kashihara-shi, Nara
    Site status: Not listed — confirm with the team
  • Asakayama General Hospital /ID# 242732
    Sakai, Osaka
    Site status: Not listed — confirm with the team
  • Hizen Psychiatric Center /ID# 243239
    Kanzaki-gun, Saga-ken
    Site status: Not listed — confirm with the team
  • Rainbow & Sea Hospital /ID# 242699
    Karatsu-shi, Saga-ken
    Site status: Not listed — confirm with the team
  • Inuo Hospital /ID# 243310
    Tosu-shi, Saga-ken
    Site status: Not listed — confirm with the team
  • Juntendo Univ Koshigaya Hospital /ID# 248502
    Koshigaya-shi, Saitama
    Site status: Not listed — confirm with the team
  • Numazu Chuo Hospital /ID# 245275
    Numazu-shi, Shizuoka
    Site status: Not listed — confirm with the team
  • Tochigi Prefectural Okamotodai Hospital /ID# 248855
    Utsunomiya, Tochigi
    Site status: Not listed — confirm with the team
  • Tokushima University Hospital /ID# 250056
    Tokushima, Tokushima
    Site status: Not listed — confirm with the team
  • Narimasu Kosei Hospital /ID# 243107
    Banqiao Qu, Tokyo
    Site status: Not listed — confirm with the team
  • Ongata Hospital /ID# 256975
    Hachioji-shi, Tokyo
    Site status: Not listed — confirm with the team
  • Nishigahara Hospital /ID# 243312
    Kita-ku, Tokyo
    Site status: Not listed — confirm with the team
  • National Center of Neurology and Psychiatry /ID# 242677
    Kodaira-shi, Tokyo
    Site status: Not listed — confirm with the team
  • Tokyo Metropolitan Matsuzawa Hospital /ID# 245272
    Setagaya-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Wakayama Medical University Hospital /ID# 251105
    Wakayama, Wakayama
    Site status: Not listed — confirm with the team
  • Shin-abuyama Hospital /ID# 243138
    Takatsuki
    Site status: Not listed — confirm with the team
  • Minamitoyama Nakagawa Hospital /ID# 243616
    Toyama
    Site status: Not listed — confirm with the team
Taiwan · 15 sites
  • Kaohsiung Municipal Kai-Syuan Psychiatric Hospital /ID# 241533
    Kaohsiung City, Kaohsiung
    Site status: Not listed — confirm with the team
  • Bali Psychiatric Center /ID# 241597
    New Taipei City, New Taipei
    Site status: Not listed — confirm with the team
  • Taipei Veterans General Hospital /ID# 241522
    Taipei City, Taipei
    Site status: Not listed — confirm with the team
  • Changhua Christian Hospital /ID# 241524
    Changhua City, Changhua County
    Site status: Not listed — confirm with the team
  • National Taiwan University Hospital - Yunlin Branch /ID# 241537
    Douliu
    Site status: Not listed — confirm with the team
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 241528
    Kaohsiung City
    Site status: Not listed — confirm with the team
  • TsaoTun Psychiatric Center, MOHW /ID# 246012
    Nantou City
    Site status: Not listed — confirm with the team
  • New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical /ID# 243653
    New Taipei City
    Site status: Not listed — confirm with the team
  • Chung Shan Medical University Hospital /ID# 241543
    Taichung
    Site status: Not listed — confirm with the team
  • Taichung Veterans General Hospital /ID# 246200
    Taichung
    Site status: Not listed — confirm with the team
  • Jianan Psychiatric Center, Ministry of Health and Welfare /ID# 241540
    Tainan
    Site status: Not listed — confirm with the team
  • Taipei City Hospital, Songde Branch /ID# 241600
    Taipei
    Site status: Not listed — confirm with the team
  • Tri-Service General Hospital Beitou Branch /ID# 241563
    Taipei
    Site status: Not listed — confirm with the team
  • Taoyuan Psychiatric Center, MOHW /ID# 241691
    Taoyuan
    Site status: Not listed — confirm with the team
  • Linkou Chang Gung Memorial Hospital /ID# 241520
    Taoyuan City
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Cariprazine, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by AbbVie, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
TerminatedNCT04825860

SEP-363856 for schizophrenia

This study was terminated in China, in Japan, in the Philippines, .... It is testing SEP-363856 for schizophrenia.